These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7496802)

  • 21. Effects of substance P and neurokinin A (substance K) on motor behavior: unique effect of substance P attributable to its amino-terminal sequence.
    Hall ME; Grantham P; Limoli J; Stewart JM
    Brain Res; 1987 Sep; 420(1):82-94. PubMed ID: 2445433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N- and C-terminal substance P fragments: differential effects on striatal [3H]substance P binding and NK1 receptor internalization.
    Michael-Titus AT; Blackburn D; Connolly Y; Priestley JV; Whelpton R
    Neuroreport; 1999 Jul; 10(10):2209-13. PubMed ID: 10424700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.
    Deschamps K; Couture R
    Br J Pharmacol; 2005 Jul; 145(6):712-27. PubMed ID: 15895109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The N-terminal domain of substance P is required for complete homologous desensitization but not phosphorylation of the rat neurokinin-1 receptor.
    Vigna SR
    Neuropeptides; 2001 Feb; 35(1):24-31. PubMed ID: 11346307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Substance P and behavior: opposite effects of N-terminal and C-terminal fragments.
    Hall ME; Stewart JM
    Peptides; 1983; 4(5):763-8. PubMed ID: 6197702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-related effects of CRF and CRF-derived peptides: dissociation of behavioral, endocrine and autonomic activity.
    Diamant M; de Wied D
    Neuroendocrinology; 1993 Jun; 57(6):1071-81. PubMed ID: 8232765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of SR 142801, a new potent non-peptide NK3 receptor antagonist on cardiovascular responses in conscious guinea-pig.
    Roccon A; Marchionni D; Nisato D
    Br J Pharmacol; 1996 Jul; 118(5):1095-102. PubMed ID: 8818331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced learning produced by injection of neurokinin substance P into the region of the nucleus basalis magnocellularis: mediation by the N-terminal sequence.
    Gerhardt P; Hasenöhrl RU; Huston JP
    Exp Neurol; 1992 Dec; 118(3):302-8. PubMed ID: 1284861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat.
    Picard P; Chrétien L; Couture R
    Br J Pharmacol; 1995 Apr; 114(8):1563-70. PubMed ID: 7541280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible role of the N-terminus of substance P in kainic acid-induced toxicity in rats.
    Velázquez RA; Sun X; Kurtz HJ; Larson AA
    Brain Res; 1993 Oct; 624(1-2):109-14. PubMed ID: 7504568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positively reinforcing effects of the neurokinin substance P in the basal forebrain: mediation by its C-terminal sequence.
    Hasenöhrl RU; Gerhardt P; Huston JP
    Exp Neurol; 1992 Feb; 115(2):282-91. PubMed ID: 1370940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular responses to intrathecal neuropeptide gamma in conscious rats: receptor characterization and mechanism of action.
    Poulat P; de Champlain J; Couture R
    Br J Pharmacol; 1996 Jan; 117(2):250-7. PubMed ID: 8789376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of substance P fragments to differentiate substance P receptors of different tissues.
    Piercey MF; Dobry PJ; Einspahr FJ; Schroeder LA; Masiques N
    Regul Pept; 1982 May; 3(5-6):337-49. PubMed ID: 6180459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for involvement of NK₃ receptors in the anxiogenic-like effect of SP6-11(C-terminal), a metabolite of substance P, in rats evaluated in the elevated plus-maze.
    Duarte FS; Duzzioni M; Leme LR; Smith Sde P; De Lima TC
    Behav Brain Res; 2016 Apr; 303():168-75. PubMed ID: 26851555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral substance P and neurokinin-1 receptors have a role in inflammatory and neuropathic orofacial pain models.
    Teodoro FC; Tronco Júnior MF; Zampronio AR; Martini AC; Rae GA; Chichorro JG
    Neuropeptides; 2013 Jun; 47(3):199-206. PubMed ID: 23177733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A fragment of substance P with specific central activity: SP(1-7).
    Stewart JM; Hall ME; Harkins J; Frederickson RC; Terenius L; Hökfelt T; Krivoy WA
    Peptides; 1982; 3(5):851-7. PubMed ID: 6184702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An antagonist of substance P N-terminal fragments, D-substance P(1-7), reveals that both nociceptive and antinociceptive effects are induced by substance P N-terminal activity during noxious chemical stimulation.
    Goettl VM; Larson AA
    Brain Res; 1998 Jan; 780(1):80-5. PubMed ID: 9473599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Substance P(1-7) antagonizes substance P-induced aversive behaviour in mice.
    Sakurada T; Kuwahara H; Takahashi K; Sakurada S; Kisara K; Terenius L
    Neurosci Lett; 1988 Dec; 95(1-3):281-5. PubMed ID: 2465511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioural effects of tachykinins and related peptides.
    Elliott PJ; Iversen SD
    Brain Res; 1986 Aug; 381(1):68-76. PubMed ID: 2428433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential activation of the epithelial and smooth muscle NK1 receptors by synthetic tachykinin agonists in guinea-pig trachea.
    Figini M; Emanueli C; Bertrand C; Sicuteri R; Regoli D; Geppetti P
    Br J Pharmacol; 1997 Jun; 121(4):773-81. PubMed ID: 9208147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.